Foot Ulcer, Diabetic Clinical Trial
Official title:
A Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Study to Assess the Safety of DERMASEAL Advanced Wound Care Dressing for the Treatment of Chronic Non-healing, Neuropathic Diabetic Foot Ulcers
The goal of this clinical trial is to determine the safety of DERMASEAL for the treatment of non-healing, neuropathic diabetic foot ulcers. The main outcome measure is safety. A total of twenty-four (24) participants will be randomized to receive up to four (4) consecutive weeks of treatment with either standard of care (SOC), plasma film + SOC, or plasma film containing silver microparticles (DERMASEAL) + SOC, with a final follow-up visit 12 weeks after the last treatment.
Status | Recruiting |
Enrollment | 24 |
Est. completion date | March 30, 2025 |
Est. primary completion date | January 31, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 21 Years and older |
Eligibility | Inclusion Criteria: 1. Men or women = 21 years of age. 2. The subject is able and willing to adhere to study procedures and informed consent is obtained. 3. A non-healing ulcer that is diabetic and neuropathic in origin, located on the foot as defined by beginning >50% below the malleoli of the ankle. 4. Target ulcer surface area between 1 - 10 cm2 after debridement with no active infection. 5. Patients with Type 1 or Type 2 diabetes (criteria for the diagnosis of diabetes mellitus per American Diabetes Association.) 6. Additional wounds may be present but not within 2 cm of the target ulcer. 7. Patient has adequate arterial perfusion of the affected extremity as demonstrated by any one of the following within the past 90 days from the time of screening: i. Toe pressure (plethysmography) >50 mm/Hg OR ii. Ankle Brachial Index (ABI) with results = 0.70 and = 1.2 OR iii. TcpO2 =30 mm Hg from the foot OR iv. Doppler arterial waveforms consistent with adequate flow in the foot (biphasic or triphasic waveforms at the ankle of affected leg) 8. Target ulcer involves a full thickness skin loss, WITHOUT exposure of tendon, muscle, or bone (University of Texas Grade 1-A or Wagner Grade 1) that has been present = 4 weeks. at the time of screening. 9. HbA1c <10% taken within 30 days prior to Visit 3. 10. Serum creatinine <3.0 mg/dl within the last 6 months. 11. Willing and able (subject or responsible caregiver) to maintain required off-loading (as applicable for the location of the ulcer). 12. Negative urine pregnancy test at Visit 3 for women of childbearing potential. i) Women participants are considered of non-childbearing potential if they are pre-menopausal with a documented hysterectomy or bilateral oophorectomy; or post-menopausal defined as the cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause; or have a serum Follicle Stimulating Hormone level confirming the post-menopausal state. Exclusion Criteria: 1. Suspected or confirmed signs/symptoms of wound infection (subjects may be rescreened if the infection has been treated.) Infection is defined as, for example: i. purulence, erythema, cellulitis, excessively high temperatures in/around the ulcer, atypical smell, and/or excessive pain in/around the ulcer (infection may be treated and subject reconsidered for study participation). ii. osteomyelitis, with necrotic soft bone. (x-ray to be obtained if in the opinion of the investigator additional confirmation of diagnosis required) 2. Patients presenting with an ulcer probing to tendon, capsule or bone (University of Texas Grade 2 or 3 or deep Wagner 2 or 3). 3. Hypersensitivity to silver or fresh frozen plasma. 4. The subject was previously entered into this study or had participated in any study drug or medical device study within 30 days of screening. 5. Currently on a treatment regimen or medications which in the opinion of the investigator are known to interfere with wound healing (for example: cancer chemotherapy or equivalent immunosuppressants, systemic steroids > 10 days of treatment, cytostatic drugs, cyclooxygenase-2 inhibitors, or radiation therapy). 6. Excessive lymphedema that in the opinion of the investigator will interfere with wound healing. 7. A cognitive, physical, or psychological condition interfering with subject's ability to comply with the treatment regimen. 8. Active Charcot foot or unstable Charcot that in the opinion of the investigator will inhibit wound healing. 9. Wounds secondary to vasculitis, neoplasms, or hematological disorders. Patients on anticoagulation medication will as in any surgical procedure, be monitored according to the protocols employed at the enrolling center. 10. An ulcer that in the opinion of the investigator is not associated with the subject's diabetic neuropathic condition. 11. Subjects is on dialysis. 12. History of radiation to the target foot. 13. Patients with uncontrolled autoimmune connective tissue diseases. 14. Patients who are pregnant, breast feeding, or unwilling to practice contraceptive methods during participation in the study, if applicable. Effective methods of contraception include: i. oral, injectable, or implanted hormonal contraceptives ii. intrauterine device or system, iii. barrier method with spermicide, or iv. bilateral tubal occlusion. 15. Patients with uncontrolled anemia (Hgb<10 g/dL in women; <12 g/dL in men) at Screening. 16. Severe malnutrition (serum albumin =2.0 with a normal C-reactive protein). 17. Wounds healed by >30% in area following the 2-week, active run-in period as measured during Visit 3. 18. Use of hyperbaric oxygen, and active dressings that include growth factors, engineered tissues, or skin substitutes (e.g., Regranex, Dermagraft, Apligraf, etc.) within 30 days of study screening. 19. Wounds >5 mm deep after sharp debridement. 20. Clinical suspicion of skin cancer at or near the ulcer location which has not been ruled out by biopsy. |
Country | Name | City | State |
---|---|---|---|
United States | Lower Extremity Institute for Research and Therapy, LLC | Boardman | Ohio |
United States | Limb Preservation Platform, Inc. | Fresno | California |
United States | Futuro Clinical Trials, LLC | McAllen | Texas |
United States | Doctors Research Network | South Miami | Florida |
Lead Sponsor | Collaborator |
---|---|
Vitruvian Medical Devices, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Adverse events | Review of adverse events associated with the topical application of a plasma film containing metallic silver microparticles in patients with chronic non-healing neuropathic diabetic foot ulcers. | 16 weeks | |
Secondary | Wound healing | Percent of study wounds healed during the post-treatment weeks 1 through 4. | 4 weeks | |
Secondary | Complete wound closure | Time to complete wound closure. | 16 weeks | |
Secondary | Wound area change | Percent area change during the post-treatment weeks 2, 4, 6 and 16 | 16 weeks | |
Secondary | Cost | Total indirect and direct costs of subject treatment during the study period | 16 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03942081 -
Diabetic Foot Ulcer Imaging- Study 2
|
N/A | |
Not yet recruiting |
NCT06023810 -
The Effect of Motivational Interviewing on Treatment Adherence, Self-Efficacy, and Satisfaction in Individuals With Diabetic Foot Ulcers
|
N/A | |
Recruiting |
NCT02838784 -
Efficacy and Safety of Artacent™ for Treatment Resistant Lower Extremity Venous and Diabetic Ulcers
|
N/A | |
Terminated |
NCT01729286 -
Health Economic Assessment of Lower Extremity Diabetic (HEALED) Ulcers With PriMatrix
|
N/A | |
Completed |
NCT01699100 -
Reduction of Plantar Pressure in Neuropathic Diabetic Foot Patients Using Insoles With Removable Pegs Design
|
N/A | |
Completed |
NCT05908968 -
Assessing the Effects of ELO Water on Diabetic Foot Ulcers
|
N/A | |
Completed |
NCT02581488 -
Use of Santyl in Diabetic Foot Ulcers
|
Phase 4 | |
Completed |
NCT02334241 -
The Sorbact® Antimicrobial Dressing in the Holistic Wound Management Of Diabetic Foot ulCers (Phase III Study)
|
N/A | |
Completed |
NCT01956162 -
Evaluation of a New Device "Orthèse Diabète" in the Healing of Foot Ulcers in Diabetic Patients
|
N/A | |
Completed |
NCT00796744 -
Safety and Efficacy Study of DSC127 in Treating Subjects With Diabetic Ulcers
|
Phase 2 | |
Recruiting |
NCT04210089 -
Total Contact Soft Cast in Diabetic Foot Ulcers
|
N/A | |
Completed |
NCT02647346 -
In-Home Assessment of a Smart Foot Mat for Prevention of Diabetic Foot Ulcers
|
N/A | |
Completed |
NCT01480362 -
Treatment Study of Negative Pressure Wound Therapy for Diabetic Foot Wounds
|
N/A | |
Terminated |
NCT01013792 -
A Comparison of an Investigational Dressing to Tegaderm Matrix Wound Dressing in the Management of Diabetic Foot Ulcers
|
N/A | |
Completed |
NCT01580917 -
Dynamic Plantar Microvascular Skin Response to Compressive Loads in At-risk Diabetic and Healthy Control: a Pilot Study
|
N/A | |
Completed |
NCT02427802 -
Study of a Topical Gentamicin-Collagen Sponge Along With Systemic Antibiotic in Infected Diabetic Foot Ulcers
|
Phase 3 | |
Completed |
NCT02451722 -
Evaluation of Pressure Distribution of Kyboot Shoes in Comparison to Other Foot Wear
|
N/A | |
Terminated |
NCT01858545 -
A Comparative Efficacy Study: Treatment for Non-healing Diabetic Foot Ulcers
|
N/A | |
Completed |
NCT00516958 -
Pilot Study of the Safety and Clinical Efficacy of Topical Dermacyn™ Wound Care to Treat Mild Diabetic Foot Infections
|
Phase 2 | |
Completed |
NCT03135535 -
Micro-mobile Foot Compression and Diabetic Foot
|
Phase 2 |